Defining the frontiers between antifungal resistance, tolerance and the concept of persistence
Open accessAbstract
A restricted number of antifungal agents are available for the therapy of fungal diseases. With the introduction of epidemiological cut-off values for each agent in important fungal pathogens based on the distribution of minimal inhibitory concentration (MIC), the distinction between wild type and drug-resistant populations has been facilitated. Antifungal resistance has been described for all currently available antifungal agents in several pathogens and most of the associated resistance mechanisms have been deciphered at the molecular level. Clinical breakpoints for some agents have been proposed and can have predictive value for the success or failure of therapy. Tolerance to antifungals has been a much more ignored area. By definition, tolerance operates at antifungal concentrations above individual intrinsic inhibitory values. Important is that tolerance to antifungal agents favours the emergence of persister cells, which are able to survive antifungal therapy and can cause relapses. Here we will review the current knowledge on antifungal tolerance, its potential mechanisms and also evaluate the role of antifungal tolerance in the efficacy of drug treatments.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Trailing growth depends on growth conditions; clinical isolates differ in this sensitivity, causing substantial variation between laboratories in its measurement.
“Like tolerance, trailing growth is sensitive to growth conditions17–19; the degree of sensitivity to these conditions differs for different clinical isolates9,(reviewed in 20), and leads to considerable laboratory-to-laboratory variation in the estimation of trailing growth.”
From Drug resistance and tolerance in fungi. (2020) · cites this paper as [20]
Section 6 reports trailing growth at neutral pH but not low pH, supporting sensitivity to growth conditions, while cautioning that the media also differed. Section 4 describes different degrees of trailing growth among C. albicans isolates. Neither passage establishes that isolates differ in their sensitivity to growth conditions or that this causes laboratory-to-laboratory variation in trailing-growth measurements; page numbers were not available in our copy. (LLM, conf=0.82)
Experimental — accuracy not yet measuredMIC measurements have been optimized to minimize or ignore residual fungal growth, termed tolerance or trailing growth, which is detected in 25-60% of clinical isolates.
“MIC measurements have been optimized to minimize or ignore residual fungal growth 4,18 , termed”
From Antifungal tolerance is a subpopulation effect distinct from resistance and is associated with persistent candidemia (2018) · cites this paper as [5]
Section 4, “What is antifungal tolerance?” (page unavailable), identifies trailing growth as residual growth above the MIC and links its degree to azole tolerance. Section 8 discusses how MIC endpoint readings can change for trailing isolates, but does not say MIC measurements were optimized to minimize or ignore that growth. The cited passages also do not substantiate the claimed 25–60% prevalence among clinical isolates. (LLM, conf=0.84)
Experimental — accuracy not yet measuredAntifungal tolerance and persistence are often overlooked in clinical practice.
“However, antifungal tolerance and persistence are often overlooked [17,47].”
From Antifungal persistence: Clinical relevance and mechanisms (2025) · cites this paper as [17]
The Abstract and §4 describe antifungal tolerance as an ignored or neglected area. Section 5 says persistence after therapy is neglected in most animal-model reports, while noting that relapses matter clinically. These passages support the broad point that both receive insufficient attention, but do not establish that they are often overlooked in clinical practice. (LLM, conf=0.85)
Experimental — accuracy not yet measuredBecause azoles are fungistatic to most yeast pathogens, it is challenging to determine whether azole tolerance is associated with persistence or with inherent properties of the drug itself.
“Given that azoles are fungistatic to most yeast pathogens, it can be challenging to determine whether azole tolerance is associated with persistence or the inherent properties of the drug itself [17].”
From Antifungal persistence: Clinical relevance and mechanisms (2025) · cites this paper as [17]
Section 4 (page not provided) identifies azoles as fungistatic and says fungal pathogens are generally tolerant to them because cells survive above the MIC. Section 5 (page not provided) says persisters may arise from increased antifungal tolerance and that their formation remains poorly understood. The paper does not specifically say that azole tolerance is difficult to distinguish from persistence versus the drug’s inherent effects. (LLM, conf=0.82)
Experimental — accuracy not yet measuredAntifungal persistence is non-heritable, although progeny of persisters may still divide into persistent and non-persistent subpopulations.
“Thirdly, antifungal persistence is non-heritable, although the progeny of persisters may still divide into persistent subpopulations and non-persistent subpopulations.”
From Antifungal persistence: Clinical relevance and mechanisms (2025) · cites this paper as [17]
Section 5 (page unavailable) describes fungal persistence as a reversible state, unlike resistance mediated by stable gene alterations. This supports the non-heritable characterization, but the paper does not say that persisters’ progeny divide into persistent and non-persistent subpopulations. (LLM, conf=0.84)
Experimental — accuracy not yet measured
Persistent strains require longer MDK99.99 because a persistent subpopulation emerges and maintains viability.
“Over time, the persistent subpopulation emerges and maintains viability, leading to longer minimum treatment durations required for 99.99% population eradication (MDK99.99) [15,17,20,21] (Fig 1).”
From Antifungal persistence: Clinical relevance and mechanisms (2025) · cites this paper as [17]
Section 5, “The occurrence of fungal persitence” (page unavailable), says that a small number of persister cells may survive antifungal therapy and remain in host tissues. It does not state that a subpopulation emerges over time or quantify the longer treatment duration needed for 99.99% eradication as MDK99.99. (LLM, conf=0.86)
Experimental — accuracy not yet measuredAntifungal persistence is a heterogeneous trait in which only a small fraction of the population, generally much less than 1%, survives drug exposure, while the majority of non-persistent cells are rapidly killed.
“Antifungal persistence is a heterogeneous trait, where only a small fraction of the population (generally <<1%) is able to survive drug exposure, while the majority of non-persistent cells are rapidly killed by the treatment.”
From Antifungal persistence: Clinical relevance and mechanisms (2025) · cites this paper as [17]
Section 5 (page unavailable) describes fungal persisters as phenotypic variants that survive antifungal therapy and are present in small numbers. It does not establish that they generally constitute much less than 1% of a population or that non-persistent cells are rapidly killed. (LLM, conf=0.87)
Experimental — accuracy not yet measuredFungal persisters exhibit a powerful antioxidant system to cope with the challenge of ROS produced by drugs or the host environment.
“Above all, fungal persisters exhibit a powerful antioxidant system to cope with the challenge of ROS produced by drugs or host environment [17].”
From Antifungal persistence: Clinical relevance and mechanisms (2025) · cites this paper as [17]
Section 5 (page unavailable) says fungal persisters can survive in the host after antifungal therapy, and describes reduced metabolic activity in C. albicans biofilm persisters. It does not say they have a powerful antioxidant system or that they use one to cope with ROS from drugs or the host; searches for “antioxidant,” “ROS,” and “reactive oxygen species” found no such passage. (LLM, conf=0.82)
Experimental — accuracy not yet measuredThe reversible nature of heteroresistance distinguishes it from conventional resistance, suggesting a non-stably heritable, potentially adaptive basis.
“The reversible nature of HR distinguishes it from conventional resistance [11], suggesting a non‐stably heritable, potentially adaptive basis.”
From Calcineurin‐Dependent Stress Adaptation Enables Caspofungin Heteroresistance Leading to Stable Resistance in <i>Candida Glabrata</i> (2026) · cites this paper as [11]
Section 5 says persistence and tolerance are reversible, unlike resistance mediated by stable gene alterations. This supports the contrast with conventional resistance, but the passage concerns persistence and tolerance, not heteroresistance; our copy does not establish that HR itself is reversible or adaptive (searched: heteroresistance). (LLM, conf=0.78)
Experimental — accuracy not yet measuredInfection outcomes are influenced by host factors as well as features of the pathogen that are not reflected by the MIC.
“This implies that infection outcomes are influenced by host factors as well as features of the pathogen that are not reflected by the MIC 5,6 .”
From Antifungal tolerance is a subpopulation effect distinct from resistance and is associated with persistent candidemia (2018) · cites this paper as [5]
Antifungal resistance is linked to specific molecular mechanisms and can be stably inherited by progeny.
“In contrast, resistance is linked to specific molecular mechanisms and can be stably inherited by progeny [15,17–19].”
From Antifungal persistence: Clinical relevance and mechanisms (2025) · cites this paper as [17]
In time-kill assays, persistent and susceptible strains take similar time to reach MDK99.
“Persistent strain and susceptible strain take similar time to reach the minimum duration of treatment that kills 99% of the population (MDK99), because initially most of the persistent strain population is susceptible to antifungal treatment and is eliminated in a manner similar to a susceptible strain.”
From Antifungal persistence: Clinical relevance and mechanisms (2025) · cites this paper as [17]
Section 5 (“The occurrence of fungal persitence”; page unavailable) describes persisters as a small number of cells that can survive antifungal therapy. Searches for MDK99, time-kill assays, and comparable initial killing found no passage stating that persistent and susceptible strains reach 99% killing in similar times or giving the proposed explanation. (LLM, conf=0.76)
Experimental — accuracy not yet measuredTolerance is reversible and results from epigenetic mechanisms, while resistance is an inheritable property determined by genes and their mutations.
“Furthermore, tolerance is reversible and results from epigenetic mechanisms, while resistance is an inheritable property determined by genes and their mutations [139].”
From Evolutionary Emergence of Drug Resistance in Candida Opportunistic Pathogens (2018) · cites this paper as [139]
Trailing growth phenomenon is related to azole tolerance and has been well documented in C. albicans.
“The ‘trailing growth’ phenomenon, describing the residual population of cells that grow at supra-MIC levels observed in broth dilution assays, can be considered related to azole tolerance and has been well documented in C. albicans.”
From Molecular and genetic basis of azole antifungal resistance in the opportunistic pathogenic fungus<i>Candida albicans</i> (2020) · cites this paper as [184]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 58 · Cited by 118
- Authors
- Delarze, E., & Sanglard, D.
- Affiliations
- Centre Hospitalier Universitaire Vaudois (CH)
- Corresponding author
- Sanglard, Dominique
- Venue
- Drug Resistance Updates
- Publisher
- Elsevier BV
- Published
- 2015-11
- Volume
- 23
- Pages
- 12-19
- ISSN
- 1368-7646 (ISSN-L)
- OpenAlex
- W1948677335
- Cited by
- 118
- References
- 58
- Citations by year
- 2026: 12 · 2025: 9 · 2024: 6 · 2023: 15 · 2022: 12 · 2021: 9 · 2020: 20 · 2019: 10 · 2018: 13 · 2017: 10 · 2016: 2
- FWCI
- 6.49
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Drug Resistance Updates (publishedVersion)
- PubMed (publishedVersion)
- SERVAL (Université de Lausanne) (publishedVersion, other-oa)
- IRIS (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Funders
- Swiss National Research Foundation (31003A_146936)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
- Life Sciences › Agricultural and Biological Sciences › Ecology, Evolution, Behavior and Systematics › Fungal Plant Pathogen Control
- Keywords
- antifungal resistance, antifungal tolerance, fungal persistence, persister cells, epidemiological cut-off values, clinical breakpoints, minimum inhibitory concentration, fungal pathogens, relapse, antifungal treatment efficacy, resistance mechanisms
- MeSH terms
- Amphotericin B, Antifungal Agents, Dose-Response Relationship, Drug, Drug Tolerance, Flucytosine, Fungi, Humans, Microbial Sensitivity Tests, Mycoses, Triazoles, Drug Resistance, Fungal, Echinocandins, Host-Pathogen Interactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review